COVID-19 rapid guideline: Managing COVID-19

Published by NICE on Dec 7, 2023

View

Disclaimer

Sponsors

Contact

Abstract

Language

en-gb

PICOS

PICO 1.1

Population
People with confirmed or suspected COVID-19
Intervention
Treatment or intermediate dose VTE prophylaxis
Comparator
Standard care (standard or intermediate-dose VTE prophylaxis as defined in the study)
Outcomes

PICO 1.1

Population
People with COVID-19
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 1.1

Population
People with COVID-19 and symptom onset in the last 7 days
Intervention
Nirmatrelvir and ritonavir
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 1.1

Population
Risk factors for People hospitalised with confirmed COVID-19 and CAPA
Intervention
People with CAPA
Comparator
People without CAPA
Outcomes

PICO 1.2

Population
People with confirmed or suspected COVID-19
Intervention
Treatment dose VTE prophylaxis
Comparator
Standard care (standard or intermediate-dose VTE prophylaxis as defined in the study)
Outcomes

PICO 1.2

Population
Signs and symptoms of people hospitalised with COVID-19 and with CAPA
Intervention
NA
Comparator
NA
Outcomes

PICO 1.3

Population
Diagnostics for CAPA
Intervention
NA
Comparator
NA
Outcomes

PICO 1.3

Population
People with moderate COVID-19
Intervention
Treatment dose VTE prophylaxis
Comparator
Standard dose VTE prophylaxis
Outcomes

PICO 1.4

Population
People with severe COVID-19
Intervention
Treatment dose VTE prophylaxis
Comparator
Standard dose VTE prophylaxis
Outcomes

PICO 1.5

Population
People with severe COVID-19
Intervention
Intermediate dose VTE prophylaxis
Comparator
Standard dose VTE prophylaxis
Outcomes

PICO 1.6

Population
People with severe COVID-19 DUPLICATE
Intervention
Treatment dose VTE prophylaxis
Comparator
Standard dose VTE prophylaxis
Outcomes

PICO 2.1

Population
People with COVID-19 (Community)
Intervention
Sotrovimab
Comparator
Placebo
Outcomes

PICO 2.1

Population
People with COVID-19 and symptom onset in the last 7 days
Intervention
Remdesivir
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 2.1

Population
People hospitalised with COVID-19 and with CAPA
Intervention
Voriconazole
Comparator
Other
Outcomes

PICO 2.2

Population
People with COVID-19 (Community)
Intervention
Casirivimab and Imdevimab (IV)
Comparator
Placebo
Outcomes

PICO 2.2

Population
People with COVID-19
Intervention
Remdesivir 5 days
Comparator
Remdesivir 10 days
Outcomes

PICO 2.3

Population
People with COVID-19 (Community)
Intervention
Casirivimab and Imdevimab (SC)
Comparator
Placebo
Outcomes

PICO 2.3

Population
People with COVID-19 (Hospitalised)
Intervention
Remdesivir
Comparator
Placebo or standard care
Outcomes

PICO 3.1

Population
People with COVID-19
Intervention
Corticosteroids
Comparator
Control
Outcomes

PICO 3.1

Population
People with COVID-19 and symptom onset in the last 7 days
Intervention
Molnupiravir
Comparator
Placebo
Outcomes

PICO 4.1

Population
People with COVID-19 (Hospitalised) ,
Intervention
Casirivimab + Imdevimab ,
Comparator
Usual Care ,
Outcomes
,

PICO 4.1

Population
Hospitalised adults with COVID-19 (non-intubated with higher oxygen requirements)
Intervention
Awake prone positioning
Comparator
Standard care
Outcomes

PICO 4.2

Population
People with COVID-19
Intervention
HFNO
Comparator
Conventional oxygen
Outcomes

PICO 4.3

Population
People with COVID-19
Intervention
HFNO
Comparator
NIV
Outcomes

PICO 4.4

Population
People with COVID-19
Intervention
CPAP
Comparator
Conventional oxygen
Outcomes

PICO 4.5

Population
People with COVID-19
Intervention
Helmet non-invasive ventilation followed by HFNO
Comparator
HFNO
Outcomes

PICO 5.1

Population
People with COVID-19
Intervention
Tocilizumab
Comparator
Standard care or placebo
Outcomes

PICO 5.2

Population
FROM V12.1 - People with COVID-19
Intervention
Tocilizumab
Comparator
Standard care or placebo
Outcomes

PICO 6.1

Population
People with COVID-19 in hospital
Intervention
Baricitinib
Comparator
Standard Care
Outcomes

PICO 9.1

Population
People with COVID-19 (Hospitalised)
Intervention
Azithromycin
Comparator
Standard care
Outcomes

PICO 9.2

Population
People with COVID-19 (Outpatients)
Intervention
Azithromycin
Comparator
Standard care
Outcomes

PICO 10.1

Population
Non-hospitalised adults with COVID-19
Intervention
Inhaled budesonide
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 11.1

Population
People with COVID-19 in hospital
Intervention
Colchicine
Comparator
Placebo or standard care
Outcomes

PICO 11.2

Population
People with COVID-19 in the community
Intervention
Colchicine
Comparator
Placebo
Outcomes

PICO 12.1

Population
People with COVID-19 (Community)
Intervention
Doxycycline plus standard care
Comparator
Standard care
Outcomes

PICO 13.1

Population
People hospitalised with COVID-19
Intervention
Ivermectin (multiple doses)
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 13.2

Population
People with hospitalised with COVID-19
Intervention
Ivermectin (Single dose)
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 13.3

Population
People with COVID-19 (Community)
Intervention
Ivermectin (multiple doses)
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 13.4

Population
People with COVID-19 (Community)
Intervention
Ivermectin (Single dose)
Comparator
Standard care, standard care plus placebo, or placebo
Outcomes

PICO 14.1

Population
People with COVID-19
Intervention
Vitamin D
Comparator
Placebo or standard care
Outcomes

PICO 15.1

Population
People with COVID-19 (Hospitalised)
Intervention
Anakinra plus standard care
Comparator
Placebo plus standard care
Outcomes